Finance

Lists
BBOT:NASDAQ
BridgeBio Oncology Therapeutics Inc
$6.76
-23.76%
(-2.10) 1D
$6.87
+1.70% (+0.11)
After hours
Closed: Sep 9, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BBOT...
Open
$8.86
High
$8.86
Low
$6.30
Mkt. cap
541.58M
Avg. vol.
255.44K
Volume
0.00
52-wk high
$14.87
52-wk low
$6.30
EPS
-$3.04
Shares outstanding
80.17M
No. of employees
88
Open
$8.86
High
$8.86
Low
$6.30
Mkt. cap
541.58M
Avg. vol.
255.44K
Volume
0.00
52-wk high
$14.87
52-wk low
$6.30
EPS
-$3.04
Shares outstanding
80.17M
No. of employees
88
News stories
From web sources and news partners
About BridgeBio Oncology Therapeutics Inc
CEO-
Employees88
Founded2016
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitebbotx.com
Analyst ratings
Based on 8 analysts giving stock ratings to BBOT in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for BBOT in the last 3 months.
Highest
Current $6.76
$25.00 (+270.10%)
Average
$21.00 (+210.88%)
Lowest
$15.00 (+122.06%)
Analyst
Recommendation
Action
Price target
Projected
Date
Biren Amin
Piper Sandler
Buy
Maintained
$21.00
+210.9%
09/09/2026
Sean McCutcheon
Raymond James
Buy
Maintained
$22.00
+225.7%
09/09/2026
Laura Prendergast
Stifel Nicolaus
Buy
Maintained
$15.00
+122.1%
09/09/2026
John Newman
Canaccord Genuity
Buy
Maintained
$20.00
+196.1%
09/09/2026
Unknown Analyst
Wedbush
Buy
Maintained
$25.00
+270.1%
09/09/2026
Sean Laaman
Morgan Stanley
Buy
Reiterated
$18.00
+166.5%
08/17/2026
Unknown Analyst
J.P. Morgan
Buy
Reiterated
$25.00
+270.1%
08/14/2026
Priyanka Grover
J.P. Morgan
Buy
Maintained
$25.00
+270.1%
08/14/2026
Mazahir Alimohamed
Oppenheimer
Buy
Reiterated
$22.00
+225.7%
08/12/2026
David Nierengarten
Wedbush
Buy
Maintained
$25.00
+270.1%
05/13/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
$22.00
+225.7%
05/13/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$29.00
+329.3%
05/01/2026
Andrew Berens
Leerink Partners
Buy
Reiterated
$41.00
+507%
03/06/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
35.05M
38.07M
39.80M
49.22M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
14.13M
5.33M
6.38M
10.96M
Operating expense
49.18M
43.41M
46.18M
60.19M
Total operating expenses
49.18M
43.41M
46.18M
60.19M
Operating income
-49.18M
-43.41M
-46.18M
-60.19M
Other non operating income
980.00K
187.00K
129.00K
182.00K
EBT including unusual items
-44.76M
-38.80M
-42.11M
-56.45M
EBT excluding unusual items
-44.76M
-38.80M
-42.11M
-56.45M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-44.76M
-38.80M
-42.11M
-56.45M
Net profit margin
-
-
-
-
Earnings per share
-1.03
-0.49
-0.53
-0.71
Interest and investment income
3.44M
4.42M
3.94M
3.55M
Interest expense
-
-
-
-
Net interest expenses
3.44M
4.42M
3.94M
3.55M
Depreciation and amortization charges
-
-
-
-
EBITDA
-49.11M
-43.32M
-46.10M
-60.11M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps